Organon & Co. (NYSE:OGN) Shares Bought by 180 Wealth Advisors LLC

180 Wealth Advisors LLC raised its holdings in Organon & Co. (NYSE:OGN) by 40.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 58,293 shares of the company’s stock after buying an additional 16,697 shares during the period. 180 Wealth Advisors LLC’s holdings in Organon & Co. were worth $870,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of OGN. Geode Capital Management LLC grew its holdings in shares of Organon & Co. by 2.0% during the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after purchasing an additional 82,220 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Organon & Co. by 39.8% during the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after purchasing an additional 988,336 shares during the last quarter. Deprince Race & Zollo Inc. grew its holdings in shares of Organon & Co. by 6.8% during the second quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock worth $70,829,000 after purchasing an additional 216,907 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after purchasing an additional 875,128 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Organon & Co. by 23.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock worth $49,843,000 after purchasing an additional 463,216 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of OGN stock opened at $15.63 on Tuesday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock’s 50-day moving average is $15.34 and its two-hundred day moving average is $18.34. The firm has a market cap of $4.03 billion, a price-to-earnings ratio of 3.10, a PEG ratio of 0.81 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the prior year, the business earned $0.78 EPS. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. Analysts predict that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.17%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio is currently 22.22%.

Wall Street Analysts Forecast Growth

Separately, Evercore ISI raised Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.